Neoadjuvant therapy is cancer treatment given before surgery to shrink a tumor, making it easier to remove. The most common forms include chemotherapy, radiation, hormone therapy, and immunotherapy. While surgery is often the primary way to remove a cancerous tumor, neoadjuvant therapy works first to reduce the tumor’s size, sometimes eliminating it entirely, so the surgery that follows can be less invasive and more effective.
How Neoadjuvant Therapy Works
The core idea is straightforward: attack the tumor before the surgeon does. By delivering treatment while the tumor is still in the body, doctors can observe in real time whether the cancer responds. A large tumor that would require extensive surgery might shrink enough to be removed through a smaller incision, leading to an easier recovery. In some cases, the tumor disappears completely, and surgery may not be needed at all.
This approach also targets cancer cells that may have already spread beyond the main tumor but are too small to detect on imaging. Chemotherapy or immunotherapy circulating through the body can reach these microscopic deposits early, before they have a chance to grow into new tumors elsewhere.
Neoadjuvant vs. Adjuvant Therapy
The difference comes down to timing. Neoadjuvant therapy happens before surgery. Adjuvant therapy happens after. Both aim to improve long-term outcomes, but they serve different strategic purposes.
Adjuvant therapy treats whatever cancer cells might remain after a tumor has been surgically removed. The problem is that some patients never start or finish adjuvant treatment because of surgical complications or reduced physical tolerance after an operation. Giving chemotherapy upfront, before surgery, tends to produce higher completion rates, especially for patients whose overall health makes tolerating post-surgical treatment a concern. Neoadjuvant treatment also provides something adjuvant therapy cannot: a live test of whether the cancer responds to the drugs being used.
Who Is a Candidate
Not every cancer patient receives neoadjuvant therapy. It’s most commonly recommended when the tumor is too large or too advanced to remove surgically right away, or when shrinking the tumor first would allow a less radical operation. Patients with inflammatory breast cancer, for example, almost always start with neoadjuvant chemotherapy because the disease typically isn’t operable at diagnosis.
For breast cancer specifically, doctors look at the tumor’s biology, including its hormone receptor status and a protein called HER2, to decide whether neoadjuvant treatment makes sense. In aggressive subtypes like triple-negative breast cancer or HER2-positive breast cancer, neoadjuvant therapy is often preferred because finding leftover cancer cells after treatment can guide decisions about additional therapy afterward. Neoadjuvant treatment is also offered when a delay before surgery is useful, for instance, to allow time for genetic testing that might influence the type of surgery performed.
What Happens During Treatment
The specific treatment depends on the cancer type and its characteristics. Chemotherapy is the most common neoadjuvant approach, but radiation, hormone-blocking therapy, and immunotherapy are all used depending on the situation. Treatment typically spans several weeks to a few months before surgery is scheduled. Throughout this period, doctors monitor the tumor with imaging to assess whether it’s responding.
After the neoadjuvant phase, surgery follows. The tissue removed during the operation is examined under a microscope to see how much cancer remains. The best possible outcome is called a pathologic complete response: no detectable cancer cells left in the surgical specimen. Achieving this is a strong signal that treatment worked well and is associated with better long-term survival. If cancer cells do remain, that information helps doctors decide whether to add or switch to different treatments afterward.
Organ Preservation
One of the most significant benefits of neoadjuvant therapy is the potential to preserve organs that might otherwise need to be removed. In breast cancer, shrinking a tumor before surgery can make the difference between a lumpectomy and a full mastectomy. In rectal cancer, the results can be even more dramatic.
Research on rectal cancer patients who achieved a complete or near-complete response after neoadjuvant chemoradiation found that a “watch and wait” approach, monitoring closely without immediate major surgery, was oncologically safe when patients were carefully selected and followed with regular endoscopy and MRI. In that study, three-year overall survival reached 96.6%, and 94.8% of patients avoided a permanent colostomy. For patients who would otherwise face life-altering surgery, these outcomes represent a meaningful quality-of-life difference.
Risks and Limitations
Neoadjuvant therapy is not without downsides. The most concerning risk is that the cancer could progress during treatment rather than shrink, potentially making surgery harder or even impossible. This happens in roughly 1% to 5% of cases, a relatively low rate, but not zero.
The treatments themselves carry toxicity. Chemotherapy and radiation cause side effects that can weaken a patient’s physical condition before they even reach the operating room. Some studies have found higher rates of surgical complications in patients who received neoadjuvant treatment compared to those who went straight to surgery. In rare instances, treatment-related toxicity before surgery can be severe or fatal, with preoperative mortality estimated between 0.5% and 2%.
There’s also the risk of overtreatment. If initial staging overestimates how advanced a cancer is, a patient might receive weeks of chemotherapy for a tumor that could have been safely removed with surgery alone. And some side effects, particularly from radiation, can develop months or years after treatment ends.
Cancers Commonly Treated This Way
Neoadjuvant therapy is standard or increasingly common in several cancer types:
- Breast cancer: Especially inflammatory, locally advanced, triple-negative, and HER2-positive subtypes where tumor response guides further treatment decisions.
- Rectal cancer: Chemoradiation before surgery is standard for locally advanced disease, with growing interest in organ preservation for strong responders.
- Lung cancer: Neoadjuvant chemotherapy and immunotherapy are used in locally advanced non-small cell lung cancer to shrink tumors, eliminate micrometastases, and provide early prognostic information.
- Bladder, esophageal, and pancreatic cancers: Neoadjuvant approaches are used to improve the chances of complete surgical removal in tumors that are borderline resectable at diagnosis.
What Response Means for Prognosis
One of the unique advantages of giving treatment before surgery is that doctors can directly measure how well it worked. When the surgical specimen shows no remaining cancer cells, a pathologic complete response, it’s one of the strongest indicators that the treatment was effective. Patients who achieve this outcome generally have lower rates of cancer recurrence and better overall survival.
When cancer cells do remain, that’s valuable information too. It tells doctors the first-line treatment wasn’t enough, and in some cancers, there are established protocols for switching to different therapies based on that finding. This ability to adapt the treatment plan in real time is something that going straight to surgery doesn’t offer.